Latest Nasdaq Listing News

AXP Energy has launched its first gas-to-power bitcoin mining operation at its Pathfinder field in Colorado, producing hydrocarbons from a new formation and planning rapid US expansion.

Renergen Limited is poised to be acquired by US-based ASP Isotopes Inc. in a deal that aims to create a powerhouse in critical helium and isotope supply chains. The merger promises expanded market access and strategic value across key industries.

AXP Energy has completed a successful 60-day gas-to-power trial at its Pathfinder Field, delivering 1.5 MW of off-grid power and generating maiden natural gas revenue. The company is accelerating its expansion plans, backed by NASDAQ-listed BitFuFu, aiming to scale operations to 25 MW by year-end.

Thrive Tribe Technologies has initiated a corporate restructure focused on revenue growth, appointed a seasoned COO, and rebranded its platform while securing venture debt funding to support expansion.

Global Uranium and Enrichment Limited has completed a transformative acquisition of the Pine Ridge Uranium Project in Wyoming, backed by a A$10 million capital raise and strategic partnership with Snow Lake Energy. This positions the company for near-term uranium production in the US’s premier ISR basin while advancing multiple other uranium assets.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

IRIS Metals has completed key drilling programs at its South Dakota lithium projects and successfully raised $8 million, positioning itself to deliver its maiden mineral resource estimate for the Beecher Project in early 2025.

Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.